Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07150520

VR-Based Optokinetic Stimulation in Multiple Sclerosis

The aim of this study is to investigate the acute effects of virtual reality-based optokinetic stimulation on postural sway and motion sickness symptoms in individuals with multiple sclerosis (MS)

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

This study will be conducted at Hacettepe University, Faculty of Physical Therapy and Rehabilitation. It will investigate the acute effects of virtual reality-based optokinetic stimulation (OKS) on postural sway and motion sickness symptoms in individuals with multiple sclerosis (MS). Participants will include MS patients with and without central vestibular dysfunction, as well as age- and sex-matched healthy controls. MS participants will first undergo vestibular function assessment using videonystagmography (VNG). Postural control will then be measured via a force platform under four conditions (bipodal/monopodal, eyes open/closed) before and after a 10-minute OKS session using Oculus Quest 2. Healthy participants will follow the same postural and OKS assessment protocol without VNG.Motion sickness and virtual reality effects will be evaluated using the Simulator Sickness Questionnaire. Data will be analyzed using appropriate parametric or non-parametric tests to compare postural sway and VR-related symptoms across groups, with significance set at p < 0.05.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be an adult aged 18-55 years
  • Have a confirmed diagnosis of MS by a neurologist (for MS groups)
  • Not have had a relapse in the last 3 months (for MS patients)
  • Have an Expanded Disability Status Scale (EDSS) score of ≤ 4 (for MS patients)
  • Be a healthy control with no condition preventing participation

Exclusion criteria

  • Have peripheral vestibular dysfunction (for MS groups)
  • Be older than 55 years
  • Have any cardiovascular, orthopedic, neurological, or other condition preventing assessments
  • Have a history of neurological disorders, head trauma, or chronic psychiatric conditions (for healthy controls)

Treatment and study plan

Virtual Reality-Based Optokinetic Stimulation (OKS)

Device

A 10-minute session of virtual reality-based optokinetic stimulation (OKS) using the Oculus Quest 2 system. The stimulation speed is set at 40°/s and the direction is determined according to Fukuda test results. Postural sway and motion sickness will be assessed before and after the intervention.

Primary outcomes

  1. Postural Sway

    Time frame: Immediately before and immediately after the 10-minute virtual reality-based optokinetic stimulation session

    Postural sway will be assessed using the FreeMED force platform under four conditions (bipodal/monopodal, eyes open/closed) before and after a 10-minute virtual reality-based optokinetic stimulation (OKS) session. Parameters include sway path, mediolateral (delta X), and anteroposterior (delta Y) displacement.

Sponsors and collaborators

Lead sponsor

Avrasya University

Other

Collaborators

  • Hacettepe University

Registry information

Official study title

Acute Effects of Virtual Reality-Based Optokinetic Stimulation in Individuals With Multiple Sclerosis: Does Central Vestibular Dysfunction Alter These Effects?

Acronym: VR-OKS-MS

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Sep 2, 2025
Registry last updated
Sep 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.